All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by AbbVie, BeOne Medicines, Johnson & Johnson, Roche, and Sobi, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
During the 2020 Annual Meeting of the Society of Hematologic Oncology (SOHO), the Lymphoma Hub was pleased to speak to Steering Committee member Nathan Fowler, MD Anderson Cancer Center, Houston, US. In this interview he provided an update on follicular lymphoma from the SOHO 2020 Meeting.
Update from SOHO 2020 on follicular lymphoma
Nathan Fowler first outlines the recent advances in the management of patients with newly diagnosed indolent lymphoma. He highlights the superiority in progression-free survival observed in patients receiving obinutuzumab + chemotherapy over rituximab + chemotherapy. He also discusses the results from the RELEVANCE trial, evaluating lenalidomide + rituximab vs rituximab + chemotherapy.
In the relapsed setting, several novel agents have been approved by the FDA in recent years, including PI3K inhibitors, lenalidomide in combination with rituximab, and the first-in-class EZH2 inhibitor, tazemetostat.
Your opinion matters
Which of the following would most increase your confidence in referring patients with R/R large B-cell lymphoma for CAR T-cell therapy?